2021 Archives
 

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention

NIH | December 21, 2021

FDA Approves APRETUDE (cabotegravir) for HIV-1 Pre-Exposure Prophylaxis

FDA | December 20, 2021

HIV Drug Resistance Report - November 2021

ReliefWeb | November 24, 2021

Injectable HIV treatment for patients in UK | HIV AIDS | Health News 

YouTube | November 22, 2021

Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter 

Aidsmap | November 5, 2021

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

NIH | November 4, 2021

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

NATAP | October 26, 2021

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results 

AIDS. 2021 Oct 13. doi: 10.1097/QAD.0000000000003085.

TAG’s 2021 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | October 2021

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

ViiV | 28 September 2021

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346

FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans

docwirenews | September 23, 2021

Agents Used in Antiretroviral Therapy

Clinical Care Options | September 2021

Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain

FIU News | September 17, 2021

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

Contagionlive.com | September 10, 2021

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep.

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | August 16, 2021

Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus 

Int J STD AIDS. 2021 Jul 23;9564624211031728. doi: 10.1177/09564624211031728

Changes to the Epclusa product label for use in pediatrics

FDA | June 2021

Changes to the Mavyret product labeling for use in pediatrics

FDA | June 2021

At Last, Generic HIV Prevention Drugs Promise Savings And Access—But Also Reveal Precarious Financing

Health Affairs | May 20, 2021

How modern medication has extended the life span of people with HIV over the past 40 years 

California News Times | May 2021

Six drugmakers are in violation of 340B statute, says HRSA 

Healthcare Finance News | May 18, 2021

Clinical Insights into New Treatment Options for HIV: Cabenuva and Vocabria 

Pharmacy Times | May 10, 2021

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Business Wire | May 4, 2021

   

Still Protected! Medicare's Six Protected Drug Classes Policy Survives Trump's Attack

ADAP Advocacy Association | April 29, 2021

Revisions to the Trogarzo (ibalizumab-uiyk) product labeling

FDA | April 26, 2021

CANN Celebrates Biden Administration Protecting Medicare Part D

Community Access national Network | March 2021

Certain HIV Meds May Trigger Weight Gain 

WebMD | March 16, 2021

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Business Wire | March 15, 2021

Another HIV Tivicay Birth Outcome: Better Infant Survival 

Medscape | MARCH 15, 2021

PAF’s Co-Pay Relief Expands Assistance to Cover Insurance Premiums (including HIV/AIDS Fund).

ADAP | MARCH 11, 2021

CROI: GILEAD'S INVESTIGATIONAL LENACAPAVIR DEMONSTRATES SUSTAINED LONG-ACTING EFFICACY THROUGH WEEK 26 IN DATA PRESENTED AT CROI
NATAP | CROI 2021 March 6-10
CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254
NATAP | CROI 2021 March 6-10
CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE
NATAP | CROI 2021 March 6-10
CROI: NNRTI MK-8507 SELECTS V106 MUTATIONS, ACTIVE AGAINST COMMON NNRTI MUTATIONS
NATAP | CROI 2021 March 6-10
CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
NATAP | CROI 2021 March 6-10
CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
NATAP | CROI 2021 March 6-10
CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
NATAP | CROI 2021 March 6-10

Revisions to TRIUMEQ and DOVATO labeling

FDA | March 2, 2021

Op-ed: Six Protected Classes and Protecting People with HIV

plus | February 26, 2021

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

ViiV Healthcare | February 24, 2021

Ask the Doctors: New HIV treatment administered monthly 

Lompoc Record | February 18, 2021

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | February 10, 2021

FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection

ViiV Healthcare | January 21, 2021

MAT Provides Patients with More Transparency Around Medicine Costs

ADAP Advocacy Association | January 21, 2021

Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).

Tivicay approved in Europe in new dispersible tablet for children with HIV 

pharmaphorum | January 14, 2021

Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries

Infectious Disease Advisor | January 11, 2021

Many health plans now must cover full cost of expensive HIV prevention drugs 

Duluth News Tribune | January 10, 2021